Ayala Pharmaceuticals, Inc (AYLA)

Etorro trading 970x250
Ayala Pharmaceuticals, Inc (AYLA) Logo

About Ayala Pharmaceuticals, Inc

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company’s lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel. Address: 4 Oppenheimer Street, Rehovot, Israel, 7670104

Ayala Pharmaceuticals, Inc News and around…

Latest news about Ayala Pharmaceuticals, Inc (AYLA) common stock and company :

What Is The Ownership Structure Like For Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA)?
03 Dec, 2021 Yahoo! Finance

If you want to know who really controls Ayala Pharmaceuticals, Inc. ( NASDAQ:AYLA ), then you'll have to look at the...

Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021
30 Nov, 2021 FinancialContent

Upgrades Sidoti & Co. upgraded the previous rating for DMC Global Inc (NASDAQ:BOOM) from Neutral to Buy. In the ...

How Much Upside is Left in Ayala Pharmaceuticals, Inc. (AYLA)? Wall Street Analysts Think 116%
18 Nov, 2021 Yahoo! Finance

The average of price targets set by Wall Street analysts indicates a potential upside of 115.8% in Ayala Pharmaceuticals, Inc. (AYLA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Misses Revenue Estimates
15 Nov, 2021 Yahoo! Finance

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 10.53% and -23.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Ayala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
15 Nov, 2021 Yahoo! Finance

- Presented Preliminary Clinical Data from 6mg Cohort of Phase 2 ACCURACY Trial of AL101 in R/M ACC Demonstrating 70% Disease Control Rate at ESMO 2021 – - Presented Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC- - Published Case Studies Highlighting Clinical Activity of AL101 with Long-Lasting Responses in Patients with Desmoid Tumors – - Enrollment in All Ongoing Studies is on Track and Have Progressed as Planned – - Mult

12 Health Care Stocks Moving In Wednesday's Intraday Session
10 Nov, 2021 FinancialContent

Gainers Seres Therapeutics (NASDAQ:MCRB) shares moved upwards by 31.29% to $9.02 during Wednesday's regular session. ...

Ayala Pharmaceuticals to Present at Jefferies London Healthcare Conference
10 Nov, 2021 Yahoo! Finance

REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 5:00pm GMT (12:00pm ET). A live webcast of the fireside chat may be

Earnings Preview: Ayala Pharmaceuticals, Inc. (AYLA) Q3 Earnings Expected to Decline
09 Nov, 2021 Yahoo! Finance

Ayala Pharmaceuticals, Inc. (AYLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Relative Strength Alert For Ayala Pharmaceuticals
18 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

The past year for Ayala Pharmaceuticals (NASDAQ:AYLA) investors has not been profitable
27 Sep, 2021 Yahoo! Finance

Investors can approximate the average market return by buying an index fund. But if you buy individual stocks, you can...

Ayala Pharmaceuticals Announces Publication Highlighting Clinical Activity of its Gamma Secretase Inhibitor AL101 in Desmoid Tumors
23 Sep, 2021 FinancialContent
Ayala Pharmaceuticals Announces Publication Highlighting Clinical Activity of its Gamma Secretase Inhibitor AL101 in Desmoid Tumors
23 Sep, 2021 Yahoo! Finance

REHOVOT, Israel and WILMINGTON, Del., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the publication of two case studies of adult patients with desmoid tumors treated with AL101 in Current Oncology. This publication highlights the potential of a gamma secretase inhibitor for the treatment o

56 Biggest Movers From Yesterday
17 Sep, 2021 FinancialContent

Check out these big penny stock gainers and losersLosers Vera Therapeutics, Inc. (NASDAQ: VERA) shares tumbled ...

Ayala Pharma Unveils New Interim Data From Rare Cancer Trial With AL101
16 Sep, 2021 FinancialContent

Ayala Pharmaceuticals Inc(NASDAQ: AYLA)announced new preliminary datafrom the 6mg cohort of its ongoing Phase 2 ...

38 Stocks Moving In Thursday's Mid-Day Session
16 Sep, 2021 FinancialContent

Gainers IronNet Cybersecurity, Inc. (NASDAQ: IRNT) shares jumped 30.4% to $41.90 amid increased retail investor interest in the ...

Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with App
16 Sep, 2021 FinancialContent
Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC
16 Sep, 2021 Yahoo! Finance

- Posters presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 - Preliminary data showed meaningful clinical activity of AL101 6mg monotherapy with 70% disease control rate - AL101 was well tolerated with manageable side effects REHOVOT, Israel and WILMINGTON, Del., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffer

Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
02 Sep, 2021 FinancialContent
Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtu
01 Sep, 2021 FinancialContent
Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
01 Sep, 2021 Yahoo! Finance

REHOVOT, Israel and WILMINGTON, Del., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced upcoming ePoster presentations at the European Society for Medical Oncology (ESMO) Virtual Congress 2021, being held September 16-September 21, 2021. Ayala will present preliminary data from the 6mg cohort

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q2 Loss, Lags Revenue Estimates
13 Aug, 2021 Yahoo! Finance

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of -19.05% and -25.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Recap: Ayala Pharmaceuticals Q2 Earnings
13 Aug, 2021 FinancialContent

Shares of Ayala Pharmaceuticals (NASDAQ:AYLA) were unchanged after the company reported Q2 results. Quarterly ...

Ayala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
13 Aug, 2021 FinancialContent
Will Ayala Pharmaceuticals, Inc. (AYLA) Report Negative Q2 Earnings? What You Should Know
05 Aug, 2021 Yahoo! Finance

Ayala Pharmaceuticals, Inc. (AYLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

We Think Ayala Pharmaceuticals (NASDAQ:AYLA) Needs To Drive Business Growth Carefully
29 Jul, 2021 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Ayala's Stock Surges After Ladenburg Initiates Coverage With Price Target Of $29
13 Jul, 2021 FinancialContent

Ayala Pharmaceuticals Inc(NASDAQ: AYLA)initiated with Buy with a $29(around 120% upside) at Ladenburg Thalmann ...

Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021
13 Jul, 2021 FinancialContent

Upgrades For Royal Dutch Shell PLC (NYSE:RDS), Barclays upgraded the previous rating of Equal-Weight to Overweight. For the first ...

58 Biggest Movers From Yesterday
13 Jul, 2021 FinancialContent

Gainers MediaCo Holding Inc. (NASDAQ: MDIA) shares jumped 311.6% to close at $17.00 on Monday after jumping 20% on Friday. State ...

12 Health Care Stocks Moving In Monday's Intraday Session
12 Jul, 2021 FinancialContent

Gainers Celldex Therapeutics (NASDAQ:CLDX) stock increased by 21.35% to $39.33 during Monday's regular session. ...

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
09 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Ayala Pharmaceuticals, Inc (AYLA) is a NASDAQ Common Stock listed in , ,

970x250